Introduction: Benign prostatic hyperplasia (BPH) is a benign neoplasm that develops from the constituent elements of the prostate. It is a common age-related condition, with more than 50% of men over 50 years old exhi...Introduction: Benign prostatic hyperplasia (BPH) is a benign neoplasm that develops from the constituent elements of the prostate. It is a common age-related condition, with more than 50% of men over 50 years old exhibiting symptoms indicative of BPH. It is the main cause of lower urinary tract symptoms (LUTS). Materials and Methods: This was a prospective, descriptive and longitudinal study over a six-month period from December 15, 2023, to May 15, 2024. All patients admitted for BPH and who received medication treatment during this period were included in the study. Results: The average age of patients was 65.4 years, with the 60 to 69-year age group being the most represented (37.18%). There was no statistical link between the level of education and the occurrence of erection dysfunction ED. 66.67% of patients suffered from ED before treatment. Age was a major risk factor. 94.87% of patients were treated with Alpha-blockers due to their tolerance and effectiveness. 14.10% of patients had a history of inguinal herniorrhaphy, often due to the strain of urination and physical labor. 46.16% of patients had hypertension. No significant link was found between comorbidities and ED. 38.45% of patients consumed tobacco or alcohol. Tobacco was a significant risk factor for ED. 57.67% of patients suffered from ED after treatment, indicating an improvement compared to 66.67% before treatment. However, 24.36% did not ejaculate during sexual intercourse. Conclusion: Medication treatment is the first-line treatment for BPH. However, it can lead to retrograde ejaculation, negatively impacting ejaculatory function. The results showed that the treatment improves patients’ sexuality (IIEF-5 score), but age and tobacco consumption increase the risk of sexual dysfunction.展开更多
目的:评估自拟强精健龙方治疗中老年男性勃起功能障碍的临床疗效。方法:选择80例确诊为勃起功能障碍的中老年患者,随机分为强精健龙方组(治疗组)40例和复方玄驹胶囊组(对照组)40例,均进行2个月的治疗,停药后随访3个月。采用勃起功能障...目的:评估自拟强精健龙方治疗中老年男性勃起功能障碍的临床疗效。方法:选择80例确诊为勃起功能障碍的中老年患者,随机分为强精健龙方组(治疗组)40例和复方玄驹胶囊组(对照组)40例,均进行2个月的治疗,停药后随访3个月。采用勃起功能障碍症状评分(international index of erectilefunction-5,IIEF-5)评估治疗前后及随访3个月后两组的疗效。结果:治疗前两组IIEF-5评分无显著差异(P>0.05),治疗后两组评分分别为(19.23±5.22)、(18.87±4.39)分,与本组治疗前均有显著差异(P<0.05),组间比较无显著差异(P>0.05)。治疗组显效18例(45.00%),有效13例(32.5%),总有效率77.5%;对照组显效16例(40.0%),有效12例(30.0%),总有效率70.0%,两组比较无统计学意义。停药3个月后两组随访IIEF-5评分分别为(17.01±2.33)、(12.01±1.98)分,差异有统计学意义(P<0.01)。结论:自拟强精健龙方和复方玄驹胶囊均能明显改善治疗中老年勃起功能障碍患者的IIEF-5评分,而强精健龙方长期疗效优势更为显著。展开更多
文摘Introduction: Benign prostatic hyperplasia (BPH) is a benign neoplasm that develops from the constituent elements of the prostate. It is a common age-related condition, with more than 50% of men over 50 years old exhibiting symptoms indicative of BPH. It is the main cause of lower urinary tract symptoms (LUTS). Materials and Methods: This was a prospective, descriptive and longitudinal study over a six-month period from December 15, 2023, to May 15, 2024. All patients admitted for BPH and who received medication treatment during this period were included in the study. Results: The average age of patients was 65.4 years, with the 60 to 69-year age group being the most represented (37.18%). There was no statistical link between the level of education and the occurrence of erection dysfunction ED. 66.67% of patients suffered from ED before treatment. Age was a major risk factor. 94.87% of patients were treated with Alpha-blockers due to their tolerance and effectiveness. 14.10% of patients had a history of inguinal herniorrhaphy, often due to the strain of urination and physical labor. 46.16% of patients had hypertension. No significant link was found between comorbidities and ED. 38.45% of patients consumed tobacco or alcohol. Tobacco was a significant risk factor for ED. 57.67% of patients suffered from ED after treatment, indicating an improvement compared to 66.67% before treatment. However, 24.36% did not ejaculate during sexual intercourse. Conclusion: Medication treatment is the first-line treatment for BPH. However, it can lead to retrograde ejaculation, negatively impacting ejaculatory function. The results showed that the treatment improves patients’ sexuality (IIEF-5 score), but age and tobacco consumption increase the risk of sexual dysfunction.
文摘目的:评估自拟强精健龙方治疗中老年男性勃起功能障碍的临床疗效。方法:选择80例确诊为勃起功能障碍的中老年患者,随机分为强精健龙方组(治疗组)40例和复方玄驹胶囊组(对照组)40例,均进行2个月的治疗,停药后随访3个月。采用勃起功能障碍症状评分(international index of erectilefunction-5,IIEF-5)评估治疗前后及随访3个月后两组的疗效。结果:治疗前两组IIEF-5评分无显著差异(P>0.05),治疗后两组评分分别为(19.23±5.22)、(18.87±4.39)分,与本组治疗前均有显著差异(P<0.05),组间比较无显著差异(P>0.05)。治疗组显效18例(45.00%),有效13例(32.5%),总有效率77.5%;对照组显效16例(40.0%),有效12例(30.0%),总有效率70.0%,两组比较无统计学意义。停药3个月后两组随访IIEF-5评分分别为(17.01±2.33)、(12.01±1.98)分,差异有统计学意义(P<0.01)。结论:自拟强精健龙方和复方玄驹胶囊均能明显改善治疗中老年勃起功能障碍患者的IIEF-5评分,而强精健龙方长期疗效优势更为显著。
